Last reviewed · How we verify
nifedipine CR tablets (Adalat)
Nifedipine is a calcium channel blocker that inhibits calcium influx into vascular smooth muscle and cardiac cells, causing vasodilation and reduced blood pressure.
Nifedipine is a calcium channel blocker that inhibits calcium influx into vascular smooth muscle and cardiac cells, causing vasodilation and reduced blood pressure. Used for Hypertension, Angina pectoris (chronic stable angina).
At a glance
| Generic name | nifedipine CR tablets (Adalat) |
|---|---|
| Sponsor | Shanghai Shyndec Pharmaceutical Co., Ltd. |
| Drug class | Calcium channel blocker (dihydropyridine) |
| Target | L-type voltage-gated calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nifedipine selectively blocks L-type calcium channels in the cell membrane, preventing calcium-dependent contraction of vascular smooth muscle. This leads to peripheral vasodilation, reduced peripheral vascular resistance, and decreased blood pressure. The drug also has mild negative inotropic effects on the heart and can reduce heart rate, contributing to its antihypertensive and antianginal effects.
Approved indications
- Hypertension
- Angina pectoris (chronic stable angina)
Common side effects
- Headache
- Flushing
- Dizziness
- Peripheral edema
- Palpitations
- Fatigue
- Nausea
Key clinical trials
- Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study (PHASE2)
- Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure (PHASE4)
- Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: